Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors

Mutations in codon 317 after treatment with imatinib and dasatinib have been reported. We reviewed patients with chronic myeloid leukemia and mutations after tyrosine kinase inhibitor (TKI) therapy. F317L was detected in 20, including 12/99 (12%) with mutation after imatinib failure, and 8/16 (50%)...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Jabbour, Elias, Kantarjian, Hagop M., Jones, Dan, Reddy, Neeli, O'Brien, Susan, Garcia-Manero, Guillermo, Burger, Jan, Cortes, Jorge
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2008
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4186640/
https://ncbi.nlm.nih.gov/pubmed/18818391
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2008-04-149948
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados